QV's GRACE implant will provide a paradigm shift in the treatment of glioblastoma (GBM), the most common form of primary brain cancer in adults that has amongst the worst outcomes of any type of cancer.
QV Bioelectronics has raised €11M across 6 funding rounds from 19 investors, most recently a round in Jan 2026. Based in Manchester, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2026-01-22 | Other | €5.2M | Angel Investors,Bruntwood SciTech,Empirical Ventures,Enterprise Cheshire and Warrington,GMC Life Sciences Fund,Greater Manchester Combined Authority (GMCA)+5 more | View deal → |
| 2025-05-08 | Grant | €1.5M | Innovate UK | View deal → |
| 2023-04-03 | Grant | €1.0M | Innovate UK | View deal → |
| 2023-01-10 | Seed | €2.3M | Catapult Ventures,ElbowBeach Capital,Northern Gritstone,Science Angel Syndicate,SOSV,The Fink Family Office | View deal → |
| 2022-02-07 | Grant | €744k | Innovate UK | View deal → |
| 2021-07-07 | Seed | €860k | Catapult Ventures,Consilience Ventures,GM & Cheshire Life Sciences Fund,SOSV | View deal → |
